August 14, 2025 — Invivyd, Inc. (Nasdaq: IVVD) has released its financial results for the quarter ending June 30, 2025, alongside recent business highlights.
PEMGARDA® (pemivibart) net product revenue reached $11.8 million in Q2 2025, marking a 413% year-over-year increase. The company’s target of near-term profitability for the first half of 2025 was not achieved but remains possible with the upcoming respiratory virus season.
Invivyd announced alignment with the U.S. FDA on a rapid pathway to full approval (BLA) of its vaccine alternative monoclonal antibody candidate, VYD2311, aimed at protecting American adults and adolescents from COVID-19. The company also reported favorable safety and pharmacokinetics data for VYD2311 from a pre-pivotal first-in-human clinical trial, including a 76-day observed half-life for the IM route of administration, suggesting potential long-term protection.
According to Marc Elia, Chairman of the Board at Invivyd, the company is entering a period of significant change, particularly with the development of VYD2311 as an alternative to COVID-19 vaccination. Bill Duke, Chief Financial Officer of Invivyd, noted the growth of the PEMGARDA base business and the potential of VYD2311 to protect against symptomatic COVID-19.
Recent business highlights include the continued growth of PEMGARDA uptake among healthcare providers and its addition to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. The company anticipates identifying a potentially best-in-class RSV candidate in Q3 2025 and a preclinical measles candidate by the end of 2025, as well as advancing efforts to support the Long COVID community through the SPEAR Study Group.
Second Quarter 2025 Financial Results:
Revenue: Reported Q2 2025 PEMGARDA net product revenue of $11.8 million, as compared to $2.3 million in Q2 2024.
Cash Position: Cash and cash equivalents were $34.9 million as of June 30, 2025.
Research & Development (R&D) Expenses (including In-Process R&D): R&D expenses were $9.6 million for the quarter ended June 30, 2025, compared to $30.3 million for the comparable period of 2024. This decrease is primarily attributable to a decrease in commercial manufacturing costs of VYD2311, a decrease in clinical trial costs related to our CANOPY Phase 3 clinical trial and a decrease in personnel-related costs.
Selling, General & Administrative (SG&A) Expenses: SG&A expenses were $16.6 million for the quarter ended June 30, 2025, compared to $21.1 million for the comparable period of 2024. This decrease is primarily attributable to a decrease in stock-based compensation expense, partially offset by increased headcount-related costs and professional services fees.
Net Loss and Net Loss per Share: Net loss was $14.7 million for the quarter ended June 30, 2025, compared to $47.2 million for the comparable period in 2024. Basic and diluted net loss per share was $0.12 for the quarter ended June 30, 2025, compared to $0.40 for the comparable period in 2024.
Contact: Media Relations (781) 208-1747, media@invivyd.com; Investor Relations (781) 208-1747, investors@invivyd.com
Source: Invivyd, Inc.
